These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

298 related items for PubMed ID: 20210770

  • 1. Mucosal healing and anti TNFs in IBD.
    van Assche G, Vermeire S, Rutgeerts P.
    Curr Drug Targets; 2010 Feb; 11(2):227-33. PubMed ID: 20210770
    [Abstract] [Full Text] [Related]

  • 2. Medical therapy and mucosal healing.
    Ferrante M, Van Assche G.
    Curr Drug Targets; 2012 Sep 01; 13(10):1294-9. PubMed ID: 22664087
    [Abstract] [Full Text] [Related]

  • 3. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW, Bickston SJ.
    Cochrane Database Syst Rev; 2008 Jan 23; (1):CD006893. PubMed ID: 18254120
    [Abstract] [Full Text] [Related]

  • 4. [TNF-alpha blocking therapy in chronic inflammatory bowel disease].
    Molnár T.
    Orv Hetil; 2009 Sep 20; 150(38):1773-9. PubMed ID: 19740722
    [Abstract] [Full Text] [Related]

  • 5. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.
    Afzali A, Wheat CL, Hu JK, Olerud JE, Lee SD.
    J Crohns Colitis; 2014 Jun 20; 8(6):480-8. PubMed ID: 24268978
    [Abstract] [Full Text] [Related]

  • 6. Tumor necrosis factor-α monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology.
    Lee TW, Fedorak RN.
    Gastroenterol Clin North Am; 2010 Sep 20; 39(3):543-57. PubMed ID: 20951917
    [Abstract] [Full Text] [Related]

  • 7. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
    Chaparro M, Barreiro-de Acosta M, Echarri A, Almendros R, Barrio J, Llao J, Gomollón F, Vera M, Cabriada JL, Guardiola J, Guerra I, Beltrán B, Roncero O, Busquets D, Taxonera C, Calvet X, Ferreiro-Iglesias R, Ollero Pena V, Bernardo D, Donday MG, Garre A, Godino A, Díaz A, Gisbert JP.
    Dig Dis Sci; 2019 Mar 20; 64(3):846-854. PubMed ID: 30426297
    [Abstract] [Full Text] [Related]

  • 8. Anti-TNF-alpha treatment strategies: results and clinical perspectives.
    D'Haens G.
    Gastroenterol Clin Biol; 2009 Jun 20; 33 Suppl 3():S209-16. PubMed ID: 20117344
    [Abstract] [Full Text] [Related]

  • 9. Is there a benefit from the concomitant use of immunosupression with anti-TNF in Crohn's disease; heads or tails?
    Lakatos PL.
    Rev Recent Clin Trials; 2009 Sep 20; 4(3):152-8. PubMed ID: 20028325
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Anti-TNF therapy in inflammatory bowel diseases: a huge review.
    Peyrin-Biroulet L.
    Minerva Gastroenterol Dietol; 2010 Jun 20; 56(2):233-43. PubMed ID: 20485259
    [Abstract] [Full Text] [Related]

  • 12. Increased hospitalizations in elderly with inflammatory bowel disease on anti-tumor necrosis factor therapy but not increased infections: a community practice experience.
    Shen H, Lipka S, Katz S.
    J Crohns Colitis; 2014 Aug 20; 8(8):898-9. PubMed ID: 24434182
    [No Abstract] [Full Text] [Related]

  • 13. Optimizing anti-TNF treatment in inflammatory bowel disease.
    Rutgeerts P, Van Assche G, Vermeire S.
    Gastroenterology; 2004 May 20; 126(6):1593-610. PubMed ID: 15168370
    [Abstract] [Full Text] [Related]

  • 14. A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action.
    Bourne T, Fossati G, Nesbitt A.
    BioDrugs; 2008 May 20; 22(5):331-7. PubMed ID: 18778114
    [Abstract] [Full Text] [Related]

  • 15. [Main therapeutic advances in IBD in 2007].
    Felley C, Mottet C, Maillard MH, Hess J, Delarive J, Michetti P.
    Rev Med Suisse; 2008 Jan 23; 4(141):200, 202-4, 206-8 passim. PubMed ID: 18335885
    [Abstract] [Full Text] [Related]

  • 16. [Crohn's disease--infliximab, adalimumab and certolizumab-pegol: clinical value of anti-TNF-alpha treatment].
    Schreiber S.
    Dtsch Med Wochenschr; 2007 Aug 23; 132(34-35):1770-4. PubMed ID: 17713889
    [Abstract] [Full Text] [Related]

  • 17. Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.
    Smith LS, Nelson M, Dolder CR.
    Ann Pharmacother; 2010 Feb 23; 44(2):333-42. PubMed ID: 20118143
    [Abstract] [Full Text] [Related]

  • 18. Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease.
    Williams CJ, Peyrin-Biroulet L, Ford AC.
    Aliment Pharmacol Ther; 2014 Mar 23; 39(5):447-58. PubMed ID: 24444171
    [Abstract] [Full Text] [Related]

  • 19. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.
    Gisbert JP, Marín AC, McNicholl AG, Chaparro M.
    Aliment Pharmacol Ther; 2015 Apr 23; 41(7):613-23. PubMed ID: 25652884
    [Abstract] [Full Text] [Related]

  • 20. Update on anti-tumor necrosis factor agents in Crohn disease.
    Singh S, Pardi DS.
    Gastroenterol Clin North Am; 2014 Sep 23; 43(3):457-78. PubMed ID: 25110253
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.